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Abstract. In this cross-sectional seroepidemiological study we sought to examine the evidence for circulation of
Rift Valley fever virus (RVFV) among herders in Madagascar and Kenya. From July 2010 to June 2012, we enrolled
459 herders and 98 controls (without ruminant exposures) and studied their sera (immunoglobulin G [IgG] and IgM
through enzyme-linked immunosorbent assay [ELISA] and plaque reduction neutralization test [PRNT] assays) for evi-
dence of previous RVFV infection. Overall, 59 (12.9%) of 459 herders and 7 (7.1%) of the 98 controls were positive by
the IgG ELISA assay. Of the 59 ELISA-positive herders, 23 (38.9%) were confirmed by the PRNT assay (21 from east-
ern Kenya). Two of the 21 PRNT-positive study subjects also had elevated IgM antibodies against RVFV suggesting
recent infection. Multivariate modeling in this study revealed that being seminomadic (odds ratio [OR] = 6.4, 95% confi-
dence interval [CI] = 2.1–15.4) was most strongly associated with antibodies against RVFV. Although we cannot know
when these infections occurred, it seems likely that some interepidemic RVFV infections are occurring among herders.
As there are disincentives regarding reporting RVFVoutbreaks in livestock or wildlife, it may be prudent to conduct peri-
odic, limited, active seroepidemiological surveillance for RVFV infections in herders, especially in eastern Kenya.
INTRODUCTION
Since its first discovery in 1931,1,2 Rift Valley fever virus
(RVFV) has been detected in various sub-Saharan countries,
as well as Egypt, Saudi Arabia, and Yemen, causing numerous
outbreaks among both animals and humans.3–6 Kenya’s most
recent Rift Valley Fever (RVF) outbreak of 2006–2007 spread
to multiple provinces and districts and resulted in nearly
400 cases of severe illness with at least 118 human deaths.5,7
Epidemiological data collected from some of the patients
demonstrated that two-thirds were exposed to a recently ill
animal before infection.8 In addition, data suggested that
other risk factors, including drinking raw milk, owning an ill
animal, working as a herdsman, and slaughtering an animal,
were also associated with RVFV infection.5,8
From January to May 2008 and from November 2008 to
March 2009, a RVFV strain, similar to that identified in the
2006–2007 outbreaks in Kenya, was identified as the causative
agent in human and animal outbreaks across Madagascar,
which resulted in a total of 26 human deaths.9 However, this
was not the first epizootic to occur in Madagascar, as out-
breaks were also reported in the east coast in 1990 and 1991,
which resulted in increased abortion rates among pregnant
cattle by 17% and 15%, respectively.10,11
Following these outbreaks, it has been strongly suggested
that enhanced surveillance should be implemented to more
effectively predict and respond to future outbreaks.9 Though
positive gains have been made to monitor RVFV in these
countries, little is known regarding the maintenance of the
virus during interepidemic periods.12–17 In an effort to better
understand the ecology of human RVFV infections, we
conducted this cross-sectional, seroepidemiological study of
persons with intense exposure to ruminants living in eastern
Kenya, western Kenya, and Madagascar.
METHODS
Study settings and design. This study was approved by
Western Institutional Review Board and institutional review
boards from collaborating institutions at each of the study
sites (eastern Kenya—KEMRI Non-SSC no. 291, western
Kenya—KEMRI SC1701, and Madagascar). Study personnel
from each study site used informed consent to enroll partici-
pants ≥ 18 years of age who had a history of contact with
ruminants. In Madagascar, participants were enrolled from
the districts of Antsirabe, Antsohihy, Ihosy, Miandrivazo,
Nosy Be, Toliara, Toliara II, and Tsiroanomandidy during the
period January–March 2012 (Figure 1A). In eastern Kenya,
participants were enrolled from the villages of Gababa, Haji
Mohamed, Hathama Chari, and Masalani in the North Eastern
Province (Figure 1B) during February 6–12, 2012. In western
Kenya, participants were enrolled from the Western Province
(Figure 1B) during July 2010 to June 2012.
Ruminant exposure was defined as having an average of
one or more cumulative hours per week exposure to camels,
cattle, goats, or sheep, either by contact through touching and/
or coming within 1 m of such animals during the 12 months
before enrollment. Participants enrolled as controls resided
in the same areas, denied having such contact, and when
possible, were loosely age, group, and gender matched to
exposed participants based on an expected final distribution
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of exposed study participants. Exclusion criteria for both
groups included individuals less than 18 years of age, having
any reported immunosuppression, or having been identified
as medically likely to have greater susceptibility to various
infectious agents.
Sample collection. Upon enrollment, participants com-
pleted an enrollment questionnaire with questions about demo-
graphics, animal and environmental exposures, and relevant
medical information. Participants then permitted a serum sam-
ple collection, which was preserved at −80°C. Aliquots of serum
were later shipped on dry ice to the University of Florida
Emerging Pathogens Institute where they were first screened
for human anti-RVF immunoglobulin G (IgG) antibodies with
an enzyme-linked immunosorbent assay (ELISA). ELISA-
positive samples were then tested with a plaque reduction
neutralization test (PRNT) for validation. Finally, PRNT-pos-
itive samples were tested for human anti-RVF IgM antibodies
with ELISA to delineate acute infections.
IgG enzyme-linked immunosorbent assay. Sera received
from Madagascar and Kenya were first heat inactivated for
30 minutes at 56°C and then screened for IgG antibodies using
a commercial RVFV human IgG ELISA kit obtained from
Biological Diagnostic Supplies Limited (Scotland, United
Kingdom) according to the manufacturer’s instructions. In
brief, plates were coated with a recombinant nucleocapsid
RVFV antigen diluted 1:1,000 in sodium bicarbonate buffer
(pH = 9.6), covered with plate seals, and incubated at 4°C
overnight. Unbound antigen was removed by washing three
times for 15 seconds each using phosphate-buffered saline
with 0.05% Tween 20 (PBS-T). Plates were then blocked with
10% (w/v) skimmed milk powder (SM) in PBS at 37°C for
1 hour. Plates were washed with PBS-T, test sera added in
duplicate at a dilution of 1:400 in PBS + 2% (w/v) SM, and
incubated for 1 hour at 37°C. Plates were washed once more,
and horseradish peroxidase (HRP)–conjugated antihuman
IgG antibody, diluted 1:25,000 in PBS + 2% (w/v) SM, was
added to each well and incubated for 1 hour at 37°C. After a
final wash, chromogenic detection of HRP was performed by
the addition of 0.1 mL of the peroxidase substrate 3,3′,5,5′-
tetramethylbenzidine (TMB) (KPL, Inc., Gaithersburg, MD),
at room temperature for 10 minutes and stopped by the addi-
tion of 0.1 mL 1 N sulfuric acid.18 Absorbance of each well at
450 nm (A450) was measured by a PowerWave HT microplate
spectrophotometer (Biotek, Winooski, VT). Negative and
positive control sera were included for each plate. Sera samples
were considered positive if their optical density (OD) calcula-
tion was ≥ 0.29 (net OD serum/net mean OD positive control).
Plaque reduction neutralization test. All samples testing
positive by the ELISA kit were further studied using PRNT
adapted from methods previously described.19,20 RVFV MP-12
vaccine strain, propagated in Vero-CCL81 cells, was used in
the PRNT assay. Sera were tested in duplicate using six 4-fold
dilutions starting with 1:10 and ending at 1:10,240. A back
titration of the diluted stock MP-12 virus was performed each
time assays were run to ascertain the titer of virus stock used
(typically, 30–60 plaque forming units/mL). A neutralization
cutoff of 80% reduction, as determined by a corresponding
back titration plate, was used to determine sera titration.
IgM enzyme-linked immunosorbent assay. To ascertain
whether an individual had evidence of an acute infection, an
indirect capture ELISA, adapted in-house following the prin-
ciples of Paweska and others,21 was used. Because of having
FIGURE 1. Maps of locations where study subjects were enrolled. (A) Location of study subjects in Madagascar. (B) Provinces in Kenya where
study subjects were enrolled: 1, Western Province (N = 200 participants); 2, Garissa County (formerly North Eastern Province) (N = 230 participants).
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a limited amount of test serum and reagents, IgM testing was
performed only for individuals who tested positive with the
PRNT assay. First, 96-well microtiter plates were coated with
a goat antihuman IgM antibody (catalog no. 01-10-03; KPL,
Inc.) at a dilution of 1:2,000 in sodium bicarbonate buffer
(pH = 9.6), covered with plate seals and incubated at 4°C
overnight. Unbound antibody was washed from the well with
PBS-T, and plates were then blocked with PBS with 5% (w/v)
SM at room temperature for 2 hours. Test sera, diluted 1:100
in PBS-T plus 5% (w/v) SM, were added to coated plates and
allowed to incubate for 1 hour at 37°C. Gamma-irradiated
RVFVantigen, obtained from BEI Resources (National Insti-
tute of Allergy and Infectious Diseases, National Institutes of
Health, RVFV, ZH501, Gamma-irradiated, NR-37380), was
diluted 1:1,000 in PBS-T with 5% (w/v) SM, added to the
plates, and allowed to incubate for 1 hour at 37°C. Rabbit
anti-RVFV polyclonal antibody, obtained from Integrated Bio-
therapeutics Inc. (catalog no. 04-0001; Gaithersburg, MD), was
diluted 1:1,000 in PBS-T with 5% SM, added to the plates, and
allowed to incubate for 1 hour at 37°C. Extra serum adsorbed
HRP-conjugated goat anti-rabbit IgG antibody (catalog
no. 074-15-061, KPL, Inc.) was diluted 1:2,000, added to each
well, and incubated for 1 hour at 37°C. All wells were washed
five times after each incubation step using PBS-T. Each plate
contained a “no antigen” negative control well to adjust for
background absorbance. Chromogenic detection of HRP and
plate reading was performed as described above. An IgM-
positive control sample was not available for this assay.
Instead, serum samples collected from six individuals with no
possible RVFV exposure were collected and included in the
assay run. IgM positivity was defined as any sample with an
average A450 OD greater than three times the standard devia-
tion plus the average A450 OD of the six negative control sera.
Statistical analysis. Bivariate χ2 tests of independence or
Fisher’s exact test were used to examine the association of
demographic variables where PRNT serological outcomes were
available. ELISA IgG positivity was used as the outcome
variable when PRNT serological outcomes were not available.
Variables determined by bivariate analyses to be statistically
associated with RVFV seropositivity (P < 0.25) were then
entered into a multivariable unconditional logistic regression
model. Backward elimination was performed and covariates
with P < 0.05 were retained in the model. Individual predic-
tors retained in the final logistic models were tested for collin-
earity using bivariate χ2 tests. Finally, Hosmer–Lemeshow χ2
statistics for goodness of fit were performed. All demographic
statistics, bivariate testing, and logistic modeling were
conducted using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Study population. In Madagascar, participants were
enrolled from the north, central, and south regions of the
country, representing each of the unique climatic regions
(Figure 1). Madagascar is an island nation with a population
of nearly 23 million, located approximately 250 miles off the
eastern coast of the African continent, south of the Equator.
It is bordered to the west by the Mozambique Channel and
TABLE 1
Demographic characteristics of the study participants enrolled in 2012, Madagascar and Kenya
Demographic characteristics
Madagascar Eastern Kenya Western Kenya
Exposed* Nonexposed Exposed* Exposed* Nonexposed
n (%) n (%) n (%) n (%) n (%)
Total 93 (100) 34 (100) 230 (100) 136 (100) 64 (100)
Gender
Male 82 (88) 11 (32) 76 (33) 61 (45) 25 (39)
Female 10 (11) 24 (71) 154 (67) 75 (55) 39 (61)
Age group (years)
18–28 32 (34) 10 (29) 58 (25) 54 (40) 21 (33)
29–44 37 (40) 11 (32) 100 (44) 39 (29) 22 (34)
45–60 18 (19) 10 (29) 55 (24) 25 (18) 9 (14)
> 60 5 (5) 4 (12) 17 (7) 18 (13) 12 (19)
Madagascar (districts)
Antsirabe 8 (9) 2 (6) – – –
Antsohihy 5 (5) 3 (9) – – –
Ihosy 44 (47) 16 (47) – – –
Miandrivazo 10 (11) 9 (26) – – –
Nosy Be 4 (4) 1 (3) – – –
Toliara 0 (0) 1 (3) – – –
Toliara II 12 (13) 1 (3) – – –
Tsiroanomandidy 9 (10) 2 (6) – – –
Eastern Kenya (village)
Gababa – – 34 (15) – –
Haji Mohamed – – 150 (65) – –
Hathama Chari – – 17 (7) – –
Masalani – – 29 (13) – –
Western Kenya (tribe)
Japadhola – – – 0 (0) 1 (1.5)
Kikuyu – – – 0 (0) 1 (1.5)
Luhya – – – 63 (9) 22 (34)
Luo – – – 29 (5) 17 (27)
Samia – – – 21 (48) 6 (9)
Teso – – – 23 (11) 17 (27)
*Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 12 months before enrollment.
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to the east by the Indian Ocean. Participants were also
enrolled from areas in the eastern and western regions of
Kenya, a country of over 44 million in population. In eastern
Kenya, individuals were enrolled in Garissa County, which is
bordered by Somalia to the east and also where RVFV cases
have been previously reported. The human populations in this
area are seminomadic pastoralists, which depend on livestock
herds for survival. In western Kenya, participants were
enrolled in the formerly named Western Province, which is
bordered by Lake Victoria to the south and Uganda to the
west. This region of Kenya has a mixed crop–livestock farm-
ing system and a high human population density, with a heavy
endemic and epidemic disease burden on both humans and
animals. Western Kenya contains a range of ecological settings
from the Lake Victoria system in the south to a semi-mountain
system on the lower slopes of Mount Elgon in the north.
We enrolled 127 participants (93 exposed and 34 controls)
from Madagascar, 230 participants (all exposed) from eastern
Kenya, and 200 participants (136 exposed and 64 controls)
from western Kenya (Table 1).
ELISA and plaque reduction neutralization test. Of the
127 samples collected from Madagascar and tested by the
ELISA assay, eight (6.3%) screened positive for IgG anti-
bodies, of which two were confirmed positive by the PRNT
assay at a sera dilution of 1:160 and 1:640. Between the two
confirmed IgG PRNT-positive samples, both were from individ-
uals with exposure to ruminants (two of 93 exposed = 2.15%
RVFV positive) (Table 2). One of the two IgG PRNT-positive
samples, which had a titer of 1:640, also tested positive by
ELISA for IgM antibodies. This sample was collected from a
man of 58 years, with daily reported exposure to cattle, who
lived in Tsiroanomandidy and had no travel history outside
Madagascar. This individual also reported monthly handling
of raw meat and butchering, frequently sleeping outside close
to his cattle, and reported regular exposure to mosquito bites.
Despite being IgM positive, there were no reported symp-
toms of fever or being sick during the last 12 months. Of the
230 samples collected from eastern Kenya and tested by the
ELISA assay, 36 (15.7%) screened positive for IgG anti-
bodies. Of these 36 samples, 21 (58.3%) were confirmed pos-
itive by PRNT assay at a sera dilution ≥ 1:40. The titer range
for the exposed confirmed positives was 1:160 to 1:2,560, and
the age ranged from 18 to 65 years with a mean of 37.6 years
(Table 2 and Figure 2). Of the 200 samples collected from
western Kenya and tested by the ELISA assay, 15 screened
positive for IgG antibodies, though, none of these samples
were confirmed positive by PRNT assay.
Bivariate and multivariate analysis. As a positive PRNT
assay is less prone to cross-reactive biases, PRNT positivity
was the outcome of choice for examining risk factor associa-
tions. Data from eastern Kenya were robust enough for exam-
ining PRNT as an outcome. However, as both Madagascar
and western Kenyan sample populations yielded few PRNT
positives, instead of PRNT, we examined ELISA IgG sero-
positivity as a surrogate for PRNT positivity. Bivariate and
multivariate modeling results are recorded in Tables 3 and 4.
Important bivariate risk factors for RVFV seropositivity
included being seminomadic, drinking water from a public
well or borehole, sleeping under a mosquito net, being bitten
by a mosquito in the past 12 months, and wearing protective
clothing when working with animals in the past 12 months
(Table 3). Only the model for eastern Kenya yielded statisti-
cally significant risk factor associations with RVFV seropositiv-
ity: being seminomadic (odds ratio [OR] = 6.4, 95% confidence
interval [CI] = 2.1–15.36) and sleeping under a mosquito net
(OR = 3.2, 95% CI = 1.1–9.6). No collinearity problems were
detected between any of the variables. Hosmer–Lemeshow
χ2 statistics for goodness of fit indicated that predictors suffi-
ciently described the data.
DISCUSSION
RVFV infections are considered as a major threat to the
agricultural economies of many of the world’s nations where
competent mosquito vectors are endemic. Although previ-
ously contained in Africa and Middle East, experts have
argued that considering modern transportation and trade
routes, RVFV poses a large threat to the European Union
TABLE 2
Demographic and exposure characteristics of the 23 study subjects
PRNT-positive for antibodies against RVFV
No. Site enrolled
Ruminant
exposed* Gender
Age
group
PRNT
titer
IgM
positive
1 Madagascar Yes Male 45–60 1:640 Yes
2 Madagascar No Male 45–60 1:160 No
3 Eastern Kenya Yes Male 45–60 1:640 No
4 Eastern Kenya Yes Female 29–44 1:160 No
5 Eastern Kenya Yes Female 29–44 1:640 No
6 Eastern Kenya Yes Female 45–60 1:640 No
7 Eastern Kenya Yes Female 29–44 1:160 No
8 Eastern Kenya Yes Female 29–44 1:640 No
9 Eastern Kenya Yes Female 29–44 1:160 No
10 Eastern Kenya Yes Male 29–44 1:160 No
11 Eastern Kenya Yes Female 29–44 1:640 No
12 Eastern Kenya Yes Female > 60 1:160 No
13 Eastern Kenya Yes Female 29–44 1:2,560 No
14 Eastern Kenya Yes Female 45–60 1:640 No
15 Eastern Kenya Yes Female 45–60 1:160 No
16 Eastern Kenya Yes Male 18–28 1:640 No
17 Eastern Kenya Yes Female 18–28 1:2,560 No
18 Eastern Kenya Yes Male 18–28 1:160 No
19 Eastern Kenya Yes Female 18–28 1:160 No
20 Eastern Kenya Yes Female 29–44 1:640 No
21 Eastern Kenya Yes Female 18–28 1:160 No
22 Eastern Kenya Yes Male 29–44 1:640 No
23 Eastern Kenya Yes Male 45–60 1:160 No
IgM = immunoglobulin M; PRNT = plaque reduction neutralization test; RVFV = Rift
Valley fever virus.
*Exposure was defined as close contact through touching and/or coming within 1 m of a
ruminant animal during the 12 months before enrollment.
FIGURE 2. Distribution of plaque reduction neutralization test
(PRNT) positives (%) by age group from eastern Kenya.
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and the United States.22,23 Realizing this threat, the U.S. gov-
ernment is investing considerable funding in understanding
the ecology of RVFV and in developing better diagnostics
and vaccines.24 As part of this effort, we conducted this cross-
sectional seroepidemiological study to assess human evidence
of RVFV infection.
In general, our seroepidemiological study did not yield evi-
dence for many unrecognized human RVFV infections in the
three geographical areas we examined. However, because
some of our seropositive study subjects were relatively young,
our data suggest that indeed some human RVFV infections
may be occurring during interepidemic periods. This would
support the notion that passive surveillance for RVFV is not
highly effective in detecting new epidemic threats. Our find-
ings are also remarkable in that seropositivity was confirmed
only among those with exposures to ruminants, and the risk
factors of being seminomadic are consistent with our under-
standing of the ecology of RVFV infections.
The use of bed netting to reduce exposure to mosquitoes
also had a positive association with RVFV seropositivity, which
may seem unexpected; however, it may be explained by con-
founders that were not assessed by our survey. Possible con-
founders include differences in vector species and behavior,
particularly as it relates to host seeking and feeding. For
example, the protective effect of bed netting would be mark-
edly reduced if RVFV mosquito vectors in a given area were
predominantly daytime biters or displayed exophagic behav-
ior. In addition, it is possible that individuals who reported
using bed netting were also more likely to be in areas with
higher densities of mosquitoes, resulting in an overall increased
risk of exposure. This finding underscores the need to better
understand vector ecology as it applies to RVFV transmission
in interepidemic areas, however, it is to be noted that bed nets
remain an effective method for the prevention of vector-borne
diseases of public health importance such as malaria.
Our study had several limitations. Its cross-sectional nature
makes it difficult for us to understand when the RVFV infec-
tions may have occurred among study subjects. Also, while
we can infer some exposure information by the age of the
seropositive subject, the precision of this association is poor.
Prospective studies are a much better approach to estimating
risk of human infection over time. The study is also limited
in that we used slightly different approaches in sampling
(sample population from eastern Kenya were all exposed)
and in questioning the study subjects (instruments differed
slightly between sites).
Considering our three sampling areas in this work and
another similar study we conducted in Saudi Arabia,25 our
TABLE 3
Unadjusted ORs for risk factors associated with evidence of previous RVFV infection based on ELISA IgG seropositivity (Madagascar and west-
ern Kenya)
Risk factor
Madagascar Western Kenya
Total N No. (%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI) Total N No. (%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Ruminant exposure*
Yes 93 6 (6.5) 1.1 (0.21, 5.8) – 136 10 (7.4) 0.94 (0.31, 2.9) –
No 34 2 (5.9) Ref. 64 5 (7.8) Ref.
Age (years)
18–28 42 3 (7.1) 1.2 (0.28, 5.4) – 75 6 (8.0) 1.1 (0.38, 3.3) –
29–44 48 0 (0) – 61 3 (4.9) 0.55 (0.15, 2.0)
45–60 28 4 (14.3) 4.0 (0.92, 17.0) 34 2 (5.9) 0.74 (0.16, 3.4)
> 60 9 1 (11.1) 2.0 (0.22, 18.2) 30 4 (13.3) 2.2 (0.66, 7.5)
Gender
Female 34 2 (5.9) 0.91 (0.17, 4.7) – 114 7 (6.1) 0.64 (0.22, 1.8) –
Male 93 6 (6.5) Ref. 86 8 (9.3) Ref.
Seminomadic
Yes 1 0 (0) – – N/A N/A N/A N/A
No 125 8 (6.4)
Drinking water from public well/borehole
Yes 58 3 (5.2) 0.70 (0.16, 3.05) – 83 6 (7.2) 0.94 (0.32, 2.7) –
No 69 5 (7.2) Ref. 117 9 (7.7) Ref.
Sleep under a mosquito net
Yes 96 5 (5.2) 0.51 (0.12, 2.28) – N/A N/A N/A N/A
No 31 3 (9.7) Ref.
Bitten by a mosquito in past 12 months
Yes 123 7 (5.7) 0.51 (0.12, 2.3) – N/A N/A N/A N/A
No 4 1 (25.0) Ref.
Wear protective clothing when working with animals in past 12 months
Yes 3 0 (0) – – N/A N/A N/A N/A
No 116 8 (6.9)
Cared for birthing animal in past 12 months
Yes 2 0 (0) – – 19 0 (0) – –
No 124 8 (6.9) 181 15 (8.3)
Butchered animal in past 12 months
Yes 67 5 (7.5) 1.5 (0.35, 6.7) – 34 3 (8.8) 1.2 (0.33, 4.7) –
No 60 3 (5.0) Ref. 166 12 (7.2) Ref.
Reported fever in past 12 months
Yes 46 4 (8.7) 1.8 (0.44, 7.7) – 120 8 (6.7) 0.74 (0.26, 2.1) –
No 81 4 (4.9) Ref. 80 7 (8.8) Ref.
CI = confidence interval; ELISA = enzyme-linked immunosorbent assay; IgG = immunoglobulin G; N/A = data were not available for this covariate; OR = odds ratio; RVFV = Rift Valley
fever virus; Ref. = Reference.
*Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 12 months before enrollment.
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findings suggest that we are not missing large outbreaks of
RVFV infections in the current surveillance and reporting
systems. However, it does seem likely that small outbreaks,
which affect both animals and man, may be missed or
unreported. While one might argue that animals are the most
sensitive sentinels for RVFVoutbreaks, there are considerable
disincentives for reporting RVFVoutbreaks. Hence, conducting
limited active surveillance for RVFV in man may be an
important supplement to the surveillance that is conducted
among domestic animals and wildlife. In particular, eastern
Kenya would seem a good site to conduct such active surveil-
lance for RVFV in herders. For instance, periodically screen-
ing subsets of herders for serological evidence of RVFV
infection at various primary care clinics and hospitals in this
region would seem a prudent and likely inexpensive addi-
tional early warning measure.
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Total N No. (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Ruminant exposure*
Yes 0 0 (0) – –
No 230 21 (9.1)
Age (years)
18–28 53 4 (7.5) 0.95 (0.40, 2.2) –
29–44 103 10 (9.7) 0.75 (0.36, 1.6)
45–60 55 5 (9.1) 1.8 (0.81, 3.8) 0.32 (0.04, 2.5)
> 60 17 1 (5.9) – –
Gender
Female 154 15 (9.7) 1.3 (0.5, 3.4) –
Male 76 6 (7.9) Ref.
Seminomadic
Yes 77 15 (19.5) 5.9 (2.2, 16.0) 6.4 (2.1, 15.4)
No 153 6 (3.9) Ref. Ref.
Drinking water from public well/borehole
Yes 65 11 (16.9) 3.2 (1.3, 7.9) –
No 165 10 (6.0) Ref.
Sleep under a mosquito net
Yes 27 6 (22.2) 3.6 (1.3, 10.2) 3.2 (1.1, 9.6)
No 203 15 (7.4) Ref. Ref.
Bitten by a mosquito in past 12 months
Yes 116 15 (12.9) 2.7 (1.0, 7.2) –
No 114 6 (5.3) Ref.
Wear protective clothing when working with animals in past 12 months
Yes 17 4 (23.5) 3.5 (1.0, 11.9) –
No 210 17 (8.1) Ref.
Cared for birthing animal in past 12 months
Yes 224 20 (8.9) 0.39 (0.04, 3.7) –
No 5 1 (20.0) Ref.
Butchered animal in past 12 months
Yes 212 20 (9.4) 1.6 (0.2, 12.5) –
No 16 1 (6.3) Ref.
Reported fever in past 12 months
Yes 186 14 (7.5) 0.43 (0.16, 1.1) –
No 44 7 (15.9) Ref.
CI = confidence interval; PRNT = plaque reduction neutralization test; OR = odds ratio; RVFV = Rift Valley fever virus.
*Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 12 months before enrollment.
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